ClinicalTrials.gg
RecruitingNCT06094556Updated Apr 13, 2025

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

A Phase 1 interventional study of SHR-1826 in Advanced Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. 18-75 years old ,Male or female.
  3. score is 0 or 1.
  4. Subjects with advanced or solid tumors that have been documented by histopathology and are not responding to or tolerated by standard treatment, or have no effective standard treatment options.
  5. Have at least one according to v1.1 criteria.
  6. Expected survival ≥3 months .
  7. With good vital organ function.
  8. .

Exclusion criteria

Exclusion Criteria:

  1. With untreated or active Central nervous system (CNS) tumor . Subjects with a history or current history of meningeal metastasis.
  2. Previous or co-existing malignant tumors.
  3. Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded.
  4. Patients with uncontrolled tumor-related pain.
  5. Received systemic antitumor therapy 4 weeks before starting study treatment; Previously receiving small molecule targeted therapy, the interval of not less than 5 half-lives of the drug can be enrolled.
  6. Previously received antibody-coupled drug therapy.
  7. Have undergone major surgery other than diagnosis or within 28 days prior to initial dosing; Minor traumatic surgery within 7 days prior to first dosing.
  8. First study subjects receiving >30Gy non-radical chest radiation within 28 days prior to administration, >30Gy chest radiation within 24 weeks prior to first administration, and ≤30Gy palliative radiation within 14 days prior to first administration;If previously received radioisotope therapy, the interval of not less than 5 half-lives of the isotope drug can be included.
  9. Is participating in another clinical study or the time of first administration is less than 4 weeks from the end of the previous clinical study (last administration), or the 5 half-life of the drug, whichever is the older.
  10. The AE caused by previous anti-tumor therapy did not recover to v5.0 grade evaluation ≤1.
  11. Other severe lung diseases that may interfere with the detection or management of drug-related pulmonary toxicity within the first three months of administration that significantly affect respiratory function; Any , connective tissue, or inflammatory disease with lung involvement; Prior left or right total lung resection.
  12. Pleural effusion, ascites, or pericardial effusion requiring intervention occurred within 2 weeks prior to the first dose.
  13. Have an active autoimmune disease, or other acquired ( infection), congenital immunodeficiency disease, or a history of organ transplantation.
  14. Have poorly controlled or severe cardiovascular disease.
  15. Known hereditary or acquired bleeding and thrombotic tendencies, and bleeding symptoms and arterial/venous thrombosis events in the 3 months prior to the first dose.
  16. Untreated active hepatitis.
  17. Subjects who had a severe infection within 30 days prior to the first dose; Patients with active pulmonary tuberculosis infection within 1 year prior to enrollment were found by medical history or CT examination, or had a history of active pulmonary tuberculosis infection more than 1 year ago but had not received regular treatment.
  18. should be administered within 30 days prior to the first dose.
  19. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  20. Known allergy to any component or of the SHR-1826 product.
  21. The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participation in the study, or interfere with the study results, as well as conditions that the investigator deems inappropriate to participate in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    SHR-1826

    Dose escalation; Dose expansion; Therapeutic effect expansion.

    Drug: SHR-1826

Interventions

  • dose is calculated based on the subjects' baseline weight.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    evaluate the safety in the doses escalation

    Time frame: 21 Days

  2. Maximum tolerated dose or Maximum-administered dose

    evaluate the safety in the doses escalation

    Time frame: Approximately 1 year

  3. Recommended Phase 2 dose (RP2D)

    evaluate the safety and curative effect in the doses escalation

    Time frame: Approximately 2 years

Secondary outcomes

  1. Maximum concentration (Cmax) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  2. Time to maximum concentration (Tmax) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  3. Areas under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  4. Areas under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  5. Half-life (t1/2) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  6. Mean retention times (MRT) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  7. Clearance rate (CL) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  8. Volume of distribution at the steady state (Vss) of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  9. Anti-drug antibody of SHR-1826

    To evaluate the pharmacokinetic characteristics of SHR-1826

    Time frame: Approximately 2 years

  10. Objective response rate (ORR)

    Preliminary evaluation of the effectiveness of SHR-1826

    Time frame: Approximately 2 years

  11. Duration of response (DoR)

    Preliminary evaluation of the effectiveness of SHR-1826

    Time frame: Approximately 2 years

  12. Disease control rate (DCR)

    Preliminary evaluation of the effectiveness of SHR-1826

    Time frame: Approximately 2 years

  13. Progression free survival (PFS)

    Preliminary evaluation of the effectiveness of SHR-1826

    Time frame: Approximately 2 years

  14. Overall survival (OS)

    Preliminary evaluation of the effectiveness of SHR-1826

    Time frame: Approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Dec 25, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094556
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Dec 25, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Apr 13, 2025

Study contacts

Yijun Jia
Contact
yijun.jia@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1826

Start the discussion